LobbyingRocket Pharmaceuticals lobbying by quarter
Rocket Pharmaceuticals RCKT's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $60K. Its first report covers Q4 2024; the issues it reports most are Pharmacy.
Rocket PharmaceuticalsRCKT
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $60K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2024 | $30K | 1 |
| Q1 2025 | $20K | 1 |
| Q2 2025 | $30K | 1 |
| Q3 2025 | $30K | 1 |
| Q4 2025 | $30K | 1 |
| Q1 2026 | $30K | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$30K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES1 reports
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| The KPM Group DC | $170K | 7 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | The KPM Group DC | Under $5,000 |
| 04/20for Q1 | The KPM Group DC | $30K |
| 01/14for Q4 2025 | The KPM Group DC | $30K |
| 25/10/13for Q3 2025 | The KPM Group DC | $30K |
| 25/07/17for Q2 2025 | The KPM Group DC | $30K |
| 25/04/21for Q1 2025 | The KPM Group DC | $20K |
| 25/01/22for Q4 2024 | The KPM Group DC | $30K |
| 25/01/21for Q4 2024 | The KPM Group DC | Under $5,000 |